Member Info for Tillywhiz

Nice medium kipper at full ask

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

30-Jan-24 16:15:36 3.30 376,693 Buy* 3.10 3.30 12.43k O

Keep em coming

3.3 on the ask

Vol 9 million

There’s a whiff of CAR T on the breeze & the Bulls are snorting at the gate

Prevail liked what they saw , let the stock price re rate for all invested

Fetch the CAR T Grog

3.20 on the ask

+ 17%

Fetch the CAR T throat massager

Pawk - maybe so

Certainly been a wild trading stock there had a couple of micro dabbles for rum cash

80% -20% for me investing to trading

Tick up as I pressed button - 2.9 + 9%

Fetch the CAR T grog nibbling at 3

Prevail - certainly liked what they saw & a much higher investment premium ,

Just a time & patience for the science to unfold

Stock 2.8 + 15%

Vol 3.6 - thin - needs higher to burst through 3

Vwap 2.77

Money moving back in after yesterdays sells in thin vol likely traders pulling out to fund elsewhere-

30-Jan-24 10:56:39 2.90 450,000 Buy* 2.70 2.90 13.05k O

Clocks ticking on CAR T let’s see what this & next week brings , imo early next week for RNS

Morning all invested- & Orph - Prevail certainly liked what they saw

We all await the next RNS & important step in Hemo CAR T science-

Imo - Prevail getting involved in sept was the solid underpinning to the future of Hemo & stock re rate - regarding CAR T

Clinical is the stock value napalm imo & as per Vlads previous podcast .

Prevail RNS paragraph & carry’s clout -

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

Prevail got involved at a premium - obviously can see the potential return on CAR T

Also

Hemo - has multi pronged science all developing

CDX - simmering on the back hob

RNS -

. This remains a potentially valuable part of our portfolio and we will also work to take this forward once our lead product has moved into the clinic.

CBR - cooking into an eventual huge banquet

RNS -

We have strengthened our team with the recruitment of additional scientists during the period, inter alia to work on our CBR/BME platform. The project has begun to attract high-level interest from authorities

CAR- T - being brought to the boil - with Prevail holding the spoon

RNS

. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Once all the above are served the stock price will be multiples of current value imo & no doubt more potential pharma deals on Hemos products on the horizon .

We all await the next update

Fetch the Hemo throat massager

For ref - stock opened at Fridays pre UT price hence showing rise opposite to Fridays late trapdoor

Vwap 2.84

We require vol or an RNS or both would suffice

Fetch the CAR T grog

Morning all invested

Fresh week & the distant whiff of an RNS , & hopefully clinical confirmation

Imo - next week for RNS - early feb

We require volume today & this week to sit above 3 p however as posted Prevail content with what they viewed & at a premium to market price

Fetch the CAR T Grog

JFTH & all

Agreed & as I noted my earlier post ,

Ortex is an accurate guide & I have used for yrs

Very little interest in shorting Hemo just CFd & micro traders after fast movement fast bucks

The money for us investors is in the clinical & Hemo science.

Great months to come , is it too early for a tot of grog ?

Regarding shorts -

There are minimal shorts open on Hemo

No flagged shorts .

High cost to borrow .

Ortex showing 100 k .- tiny

The IG figure is 9% of stock invested through IG on Hemo not 9% of Hemo stock so could well be very small number .& little or no effect on the stock price in the scheme of things .

Most of the noise on these forums comes from CFD traders after fast bucks in either direction .

& Traders riding the RNS waves .

Demand for stock increasing is the north driver , imo

A positive RNS regarding clinical confirmation will certainly propel the stock price & far outweigh any trading movements .imo

Fetch the CAR T Grog

Morning all invested

We all await the next RNS & important step in Hemo CAR T science-

Imo - Prevail getting involved in sept was the solid underpinning to the future of Hemo & stock re rate - regarding CAR T

Clinical is the stock value napalm imo & as per Vlads previous podcast .

Prevail RNS paragraph & carry’s clout -

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

Prevail got involved at a premium - obviously can see the potential return on CAR T

Also

Hemo - has multi pronged science all developing

CDX - simmering on the back hob

RNS -

. This remains a potentially valuable part of our portfolio and we will also work to take this forward once our lead product has moved into the clinic.

CBR - cooking into an eventual huge banquet

RNS -

We have strengthened our team with the recruitment of additional scientists during the period, inter alia to work on our CBR/BME platform. The project has begun to attract high-level interest from authorities

CAR- T - being brought to the boil - with Prevail holding the spoon

RNS

. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Once all the above are served the stock price will be multiples of current value imo & no doubt more potential pharma deals on Hemos products on the horizon .

We all await the next update

Fetch the Hemo throat massager

Closing Numbers & another session passes

Stock price - 2.9 flat

Volume - 4.5 million- thin - needs much higher

Vwap 2.9 - barely moved all session

All invested patiently await RNS update on clinical confirmation as noted on Ortex plenty of exposure & big pharmas will have there eyes on developments - imo .

Have a superb weekend all & re group on Monday a.m

Scottydog & all

Another goading idiot

Yes I may be an older man , in fact a dad & a Grandad , & for that reason I worry for my grandkids on the internet with D.ickheads like you the Brady bunch chums ,

goading strangers for self gratification

I am an investor in many stocks including EUA & Hemo & have been for years , no agenda just crap humour.

Shall I embarrass yourself &dig your post out where you sold all EUA stock in 2019 before the bank engagement at 0.7 p , then traded it badly in subsequent yrs , hence your anger & lack of self responsibility like your buffoon chums .

Rums & expose the dipsticks all Round

What’s up Herbert , no cocoa pops left for you ?

What a sad existence you lead ,

Wake up - goad investors

All day long - goad investors

Markets close - continue to goad investors

What you doing here , why not do some actual investing ?

Had a belly full of your gobby chums yesterday, is it your turn today ,

Toxic Brady Bunch rotation meanwhile you’re all trading it , unbelievable.

Rums & toxic traders all round

For reference

Vwap 2.92 to start

We need volume increase

Fetch the Friday CAR T grog

Morning

Great exposure for Hemos superb science ,

As fellow investors have also noted

Early feb for update imo

Let’s see what Fridays session brings

Continued -

7. GenEdit and Genentech Forge Alliance to Tackle Autoimmune Disease With Nucleic Acid-Based Approaches

GenEdit and Genentech have entered a collaboration in which the 2 companies will utilize GenEdit's NanoGalaxy platform in discovery and development activities focused on hydrophilic nanoparticles for use in the delivery of Genentech's nucleic acid-based medicines. "Genentech is a leader in advancing breakthrough science to advance the development of novel therapeutic modalities," Kunwoo Lee, PhD, the CEO of GenEdit, said in a statement. "This collaboration underscores the promise of GenEdit's NanoGalaxy platform to deliver nucleic acid-based medicines via our hydrophilic nanoparticle technology."

8. Blue Cross Blue Shield Will Provide Coverage for Sickle Cell Disease Gene Therapies

Blue Cross Blue Shield has become the first health insurance company in the United States to agree to provide coverage for the 2 sickle cell disease gene therapies recently approved by the FDA, Vertex Pharmaceuticals' and CRISPR Therapeutics' exagamglogene autotemcel (exa-cel, marketed as Casgevy) and bluebird bio's lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia). The cost of both one-time treatments are in the range of millions of dollars.

9. Solvias to Handle Release Testing for Exa-cel in Sickle Cell Disease

Solvias, a chemistry, manufacturing, and control (CMC) analytics company, has inked an agreement with Vertex Pharmaceuticals to handle release testing activities for exa-cel, which is the first CRISPR-based gene therapy to have received FDA approval in the US. "Solvias is honored to be playing a critical role in delivering this breakthrough therapy to patients," Archie Cullen, BS, MBA, the CEO of Solvias, said in a statement.

Fetch the CAR T Grog for all Hemo investors

JFTH, Chris & all invested

Just for reading - here is the rest of the article with the other companies mentioned -

3. Experts Weigh In on Exa-cel's FDA Approval for Transfusion-Dependent Thalassemia

On January 16, 2024, Vertex Pharmaceuticals' and CRISPR Therapeutics' exagamglogene autotemcel (exa-cel; marketed as Casgevy), an autologous CRISPR-based gene-edited cell therapy, was approved by the FDA for the treatment of patients 12 years and older with transfusion-dependent beta thalassemia (TDT). In light of this major decision by the FDA, CGTLive™ decided to reach out to several experts to get their thoughts on how exa-cel could impact the landscape of care for TDT.

4. Autolus Therapeutics' Obe-cel Will Be Reviewed by the FDA for the Treatment of R/R B-ALL

Autolus Therapeutics' biologics license application (BLA) for obecabatagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-Cell acute lymphoblastic leukemia (ALL) has been accepted for filing by the FDA, with a Prescription Drug User Fee Act date set for November 16, 2024.

5. BlueRock Licenses FUJIFILM Cellular Dynamics' and Opsis Therapeutics' Investigational iPSC Therapy

OpCT-001 is an induced pluripotent stem cell (iPSC) derived cell therapy currently in development for the treatment of primary photoreceptor diseases. BlueRock, which plans to file an IND for the therapy this year,optioned to exclusively license it under an existing research and development collaboration agreement established between the 3 companies in 2021.

6. Orchard Therapeutics Officially Becomes Part of Kyowa Kirin

Kyowa Kirin has stated that its previously-announced agreement to acquire Orchard Therapeutics has been completed, with Orchard now being a wholly-owned subsidiary of the Japanese pharmaceutical company. Orchard Therapeutics' atidarsageneautotemcel (arsa-cel, Libmeldy) is a cell therapy for the treatment of metachromatic leukodystrophy that is approved in the European Union, UK, Iceland, Liechtenstein, and Norway, but remains an investigational therapy in the United States. Recently, the FDA accepted a biologics license application for arsa-cel with priority review.

Cont…

Ortex - popped up today on the CAR T sector listing 9 companies including Hemo

( if been shared already apologies )

News

The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive™'s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.

Have a cell and gene therapy news update you'd like to share with our editorial team? Tag us on social and use #AroundTheHelix!

1. FDA Requests Black Box Warning Be Added for All Currently Approved CAR-T Therapies

The FDA has requested that black box warnings related to secondary cancer risks be added to all 6 of the chimeric antigen receptor T-cell (CAR-T) therapy products currently approved by the agency for use in the United States.

2. Hemogenyx Sends the FDA a Complete Response Related to the IND Hold on AML CAR-T HEMO-CAR-T

Hemogenyx Pharmaceuticals has submitted a complete response to the FDA regarding the clinical hold that was placed on the company's investigational new drug (IND) application for HEMO-CAR-T, an autologous CAR-T therapy developed with the use of Hemogenyx's proprietary humanized monoclonal antibody against an acute myeloid leukemia target.

All invested await clinical update via RNS .